跳到主要內容區塊 :::

English

Personal Information:

 

Name:  I-Tsu Chyuan (全以祖)
Work address: Department of Internal Medicine
Cathay General Hospital
No.280, Sec. 4, Ren’ai Rd., Da’an Dist., Taipei City 106, Taiwan(R.O.C.)
Tel: (886)-2-27082121 ext. 3210

 

Present position:

  1. Chief Director, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
  2. Deputy Director, Department of Medical Research, Cathay General Hospital, Taipei, Taiwa
  3. Principle Investigator, Cathay Medical Research Institute, Cathay General Hospital, Taipei, Taiwan
  4. Deputy Executive Secretary, Human Research Protection Center, Cathay General Hospital, Taipei, Taiwan
  5. Attending Physician, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
  6. Assistant Professor, School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
  7. Adjunct Attending Physician, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

 

Education:

2018–2020 Post-doctoral fellows, Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan
2014–2018 PhD. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan
1998–2005 M.D. School of Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.

 

Professional Experience:

2020 Chief Director, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
2020 Deputy Executive Secretary, Human Research Protection Center, Cathay General Hospital, Taipei, Taiwan
2019 Deputy director, Department of Medical Research, Cathay General Hospital, Taipei, Taiwan
2019 Principle Investigator, Cathay Medical Research Institute, Cathay General Hospital, Taipei, Taiwan
2019 Assistant Professor, School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan
2014 ttending Physician, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Cathay General Hospital, Taipei, Taiwan
2012 Adjunct Attending Physician, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan
2012–2014 University Hospital, Taipei, Taiwan Attending Physician, Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Hsin-Chu Branch, Hsin Chu, Taiwan
2010–2012 Fellowship, Division of Allergy, Division of Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

 

Professional Societies:

Taiwan Rheumatology Association
Chinese Society of Immunology
Taiwan Society of Internal Medicine
Taiwan Society of Ultrasound in Medicine

 

Special Honors and Awards:

2019  The Shen Shui-De Award in Chinese Immunology Society

2019  Travel Award in 7th Annual Meeting of Asian Organization for Crohn’s and Colitis

2018  The Shen Shui-De Award in Chinese Immunology Society

2018 The Award for Best Oral Presentation in the 33rd Joint Annual Conference of Biomedical Science

2016  The Award for Best Oral Presentation in Chinese Immunology Society

2015 The Shen Shui-De Award in Chinese Immunology Society

 

Publications:

  1. Chyuan IT, Hsu PN. TRAIL regulates T cell activation and suppresses inflammation in autoimmune diseases. Cell Mol Immunol. 2020;17(12):1281-1283. (SCI)
  2. Wu CS, Chyuan IT, Chiu YL, Chen WL, Shen CY, Hsu PN. Preserved specific anti-viral T-cell response but associated with decreased lupus activity in SLE patients with cytomegalovirus infection. Rheumatology (Oxford). 2020; 59(11):3340-3349. (SCI)
  3. Chyuan IT, Lai JH. New insights into the IL-12 and IL-23: from a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem Pharmacol. 2020;175:113928. (SCI)
  4. Sung CC, Horng JH, Siao SH, Chyuan IT, Tsai HF, Chen PJ, Hsu PN. Asialo GM1-positive liver-resident CD8 T cells that express CD44 and LFA-1 are essential for immune clearance of hepatitis B virus. Cell Mol Immunol. 2020 (in press) (SCI)
  5. *Huang SW, *Chyuan IT, Shiue C, Yu MC, Hsu YF, Hsu MJ. Lovastatin-mediated MCF-7 cancer cell death involves LKB1-AMPK-p38MAPK-p53-survivin signalling cascade. J Cell Mol Med. 2020;24(2):1822-1836 (* co-first author). (SCI)
  6. Tzeng HT, Chyuan IT, Chen WY. Shaping of innate immune response by fatty acid metabolite palmitate. Cells. 2019;8(12). (SCI)
  7. Chyuan IT, Tzeng HT, Chen JY. Signaling pathways of type I and type III interferons and targeted therapies in systemic lupus erythematosus. 2019;8(9). (SCI)
  8. Chyuan IT, Tsai HF, Wu CS, Hsu PN. TRAIL suppresses gut inflammation and inhibits colitogenic T cell activation in experimental colitis via an apoptosis-independent pathway. Mucosal Immunol. 2019;12(4):980-989 (SCI)
  9. Liao HJ, Tsai HF, Wu CS, Chyuan IT, Hsu PN. TRAIL inhibits RANK signaling and suppresses osteoclast activation via inhibiting lipid raft assembly and TRAF6 recruitment. Cell Death Dis. 2019;10(2):77. (SCI)
  10. Chyuan IT, Chen JY. Role of Interleukin-(IL-)17 in the pathogenesis and targeted therapies in spondyloarthropathies. Mediators Inflamm. 2018;2018:2403935. (SCI)
  11. Chyuan IT, Tsai HF, Wu CS, Sung CC, Hsu PN. TRAIL-mediated suppression of T cell receptor signaling inhibits T cell activation and in?ammation in experimental autoimmune encephalomyelitis. Front Immunol. 2018;9:15. (SCI)
  12. Chyuan IT, Hsu PN. Tumor necrosis factor: The key to hepatitis B viral clearance. Cell Mol Immunol. 2018;15(8):731-733. (SCI)
  13. Yang NY, Wang CY, Chyuan IT, Wu KJ, Tu YK, Chang CW, Hsu PN, Kuo MY, Chen YW. Significant association of rheumatoid arthritis-related inflammatory markers with non-surgical periodontal therapy. J Formos Med Assoc. 2018;117(11):1003-1010. (SCI)
  14. Chyuan IT, Tsai HF, Liao HJ, Wu CS, Hsu PN. An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T cell activation in inflammatory arthritis. Cell Mol Immunol. 2018;15(9):846-857. (SCI)
  15. Tsai HF, Wu CS, Chen YL, Liao HJ, Chyuan IT, Hsu PN. Galectin-3 suppresses mucosal inflammation and reduces disease severity in experimental colitis. J Mol Med (Berl). 2016;94(5):545-56 (SCI)
  16. Wang CY, Chyuan IT, Wang YL, Kuo MY, Chang CW, Wu KJ, Hsu PN, Nagasawa T, Wara-Aswapati N, Chen YW. β2-glycoprotein I-dependent anti-CL antibodies associated with periodonitis in SLE patients. J Periodontol. 2015;86(8):995-1004. (SCI)
  17. Chyuan IT, Tsai HF, Tzeng HT, Sung CC, Wu CS, Chen PJ, Hsu PN. Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T cell exhaustion in a mouse model. Cell Mol Immunol. 2015;12(3):317-25. (SCI)
  18. *Liao HJ, *Chyuan IT, Wu CS, Lin SW, Chen KH, Tsai HF, Hsu PN. Increased neutrophil infiltration, IL-1 production and a SAPHO syndrome-like phenotype in PSTPIP2-deficient mice. 2015;54(7):1317-26 (* co-first author) (SCI)
  19. Chyuan IT, Tsai TH, Chang TH, Wu CS. Ustekinumab treatment in a patient with psoriasis and systemic lupus erythematosus. 2015;24(6):650-1. (SCI)
  20. Tzeng HT, Tsai HF, Chyuan IT, Liao HJ, Chen CJ, Chen PJ, Hsu PN. Tumor necrosis factor-alpha induced by hepatitis B virus core mediating the immune response for hepatitis B viral clearance in mice model. PLoS One. 2014;9(7):e103008. (SCI)
  21. Wu CS, Hu CY, Tsai HF, Chyuan IT, Chan CJ, Chang SK, Hsu PN. Elevated serum level of growth arrest-specific protein 6 (Gas6) in systemic lupus erythematosus patients is associated with nephritis and cutaneous vasculitis. Rheumatol Int. 2014;34(5):625-9. (SCI)

 

Conference:

  1. The 7th Annual Meeting of Asian Organization for Crohn’s and Colitis (AOCC), Taipei, Taiwan, 2019/06/14-06/16. “TRAIL suppresses gut inflammation and inhibits colitogeic T cell activation in experimental colitis via an apoptosis-independent pathway”, Poster. Supported by AOCC.
  2. The Federation of Immunological Societies of Asia-Oceania Congress (FIMSA), Bangkok, Thailand, 2018/11/10-11/13. “An apoptosis-independent role of TRAIL mediates suppression of T cell activation and autoimmune inflammation in experimental autoimmune encephalomyelitis”, Poster. Supported by MOST.
  3. The 33th Joint Annual Conference of Biomedical Science, Taipei, Taiwan, 2018/10/28. “A novel immune regulatory role of TRAIL in T cell activation and autoimmune inflammation via an apoptosis independent pathway”, Oral. [Best Oral Award]
  4. Cytokine, Kanazawa, Japan, 2017/10/29-11/02. “TRAIL suppresses joint inflammation and osteoclastogenesis through inhibiting activated T cell responses in inflammatory arthritis”, Oral. Supported by MOST.
  5. The 16th TNF Superfamily Meeting. Singapore, 2017/04/17-04/21. “An apoptosis-independent role of TRAIL in suppressing joint inflammation and inhibiting T cell activation in inflammatory arthritis”, Oral. Supported by MOST.
  6. The 16th International Congress of Immunology (ICI). Melbourne, Australia, 2016/08/21-08/26. “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) suppresses joint inflammation and bone erosion by inhibiting T cell activation in experimental arthritis”, Oral. Supported by MOST.
  7. The Congress of the Chinese Society of Immunology. Taipei, Taiwan, 2016. “TRAIL modulates experimental autoimmune encephalomyelitis (EAE) by directly inhibiting myelin-specific T cells activation via TRAIL receptor signaling”, Oral. [Best Oral Award]
  8. The Congress of the Chinese Society of Immunology. Taipei, Taiwan, 2015. “Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse model”, Poster.
  9. The Congress of the Chinese Society of Immunology. Taipei, Taiwan, 2014. “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) suppresses joint damage and protects against bone loss by inhibiting T cell activation and inflammation in experimental arthritis”, Oral.
  10. The 15th International Congress of Immunology. Milan, Italy, 2013/08/22-08/27. “Neutrophil infiltration, increased IL-1 production and SAPHO syndrome-like phenotype in PSTPIP2 deficient mice”, Poster. Supported by MOST.

更新時間:2021/3/18